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Seroprevalence studies are crucial both for estimating the prevalence of SARS-CoV-2
exposure and to provide a measure for the efficiency of the confinement measures.
Portuguese universities were closed on March 16th 2020, when Portugal only registered
62 SARS-CoV-2 infection cases per million. We have validated a SARS-CoV-2 ELISA
assay to a stabilized full-length spike protein using 216 pre-pandemic and 19 molecularly
diagnosed SARS-CoV-2 positive individual’s samples. At NOVA University of Lisbon,
presential work was partially resumed on May 25th with staggered schedules. From
June 15th to 30th, 3–4 weeks after the easing of confinement measures, we screened
1,636 collaborators of NOVA university of Lisbon for the presence of SARS-CoV-2
spike specific IgA and IgG antibodies. We found that spike-specific IgG in 50 of 1,636
participants (3.0%), none of which had anti-spike IgA antibodies. As participants self-
reported as asymptomatic or paucisymptomatic, our study also provides a measurement
of the prevalence of asymptomatic/paucisymptomatic SARS-CoV-2 infections. Our study
suggests that essential workers have a 2-fold increase in viral exposure, when compared
to non-essential workers that observed confinement. Additional serological surveys in
different population subgroups will paint a broader picture of the effect of the confinement
measures in the broader community.
Keywords: SARS-CoV2, serosurvey, IgA and IgG, pauci/asymptomatic COVID-19 prevalence, post-confinement
community setting
INTRODUCTION
In late 2019, SARS-CoV-2 emerged as a novel human coronavirus, and its subsequent worldwide
spread has led to ∼47,596,852 infections and to ∼1,216,357 deaths (https://covid19.who.int).
COVID-19, the clinical disease caused by SARS-CoV-2 infection, spans from mild self-limiting
disease to acute respiratory distress and death (1–3). Even though testing capacity has increased
sharply in the past months, most of SARS-CoV-2 reported cases have been restricted to
symptomatic individuals and those having close contact with confirmed patients. Notwithstanding,
subclinical asymptomatic infections are reported to account for∼40–45% of infections and thought
Gonçalves et al. SARS-CoV-2 Seroprevalence Following Confinement Relieve
to be an important contributor for SARS-CoV-2 transmission
(4). Thus, assessing the cumulative prevalence of SARS-
CoV-2 infection, including accounting for asymptomatic or
subclinical cases, might be critical to underpin the SARS-CoV-2
contagiousness and the success of confinement measures (5, 6).
Serological tests, which detect antibodies specific for SARS-
CoV-2, allow for a more accurate estimate of the cumulative
prevalence of SARS-CoV-2 infection in a population compared to
the viral diagnostic test; as SARS-CoV-2 antibodies, in particular
IgG, persist after viral clearance (7). Most of the SARS-CoV-2
serological tests developed so far detect antibodies made against
the viral protein Spike (8–13). Spike is a trimeric glycoprotein
protruding from SARS-CoV-2 viral membrane that mediates
viral entry into the host cell (14, 15). These features make spike
the preferential target in the development of serological tests and
vaccine candidates. Hence, the serological assay used in this study
to characterize anti-SARS-CoV-2 specific antibody response
makes use of the trimerized, stabilized ectodomain of the spike
protein. It is based on an enzyme-linked immunosorbent assay
(ELISA) initially developed in early 2020 by Florian Krammer
group at Mount Sinai’s CLIA laboratory where it received
New York State Department of Health (NYSDOH) and FDA
emergency use authorization (8, 9).
On March 2nd 2020, the first case of coronavirus disease
2019 (COVID-19) was diagnosed in Portugal (16). On March
16th confinement measures including the closure of schools
and universities and encouragement of remote work were
enforced. Even though Portugal has one of the highest SARS-
CoV-2 infection testing rate, testing has been mainly limited to
symptomatic cases and their close contacts, leaving unaccounted
asymptomatic and subclinical cases. Seroprevalence studies
provide relevant epidemiological information to determine
SARS-CoV-2 viral exposures within individuals and in the
population (17). In view of the relative low prevalence of SARS-
CoV-2 infection in most of the countries analyzed so far (7, 18–
21), ELISA tests being developed need to be not only sensitive
but also highly specific (22). Moreover, serological assays must
be of straight-forward implementation and provide information
that can be easily compared between distinct populations and
geographic localizations.
Monitoring the seroprevalence in professional groups that
adhered, to distinct extents, to remote work as early as
March 8th 2020 is very relevant for evaluating the efficacy
of the confinement measures. In NOVA University of Lisbon,
even though remote work remained encouraged, the easing
up of confinement measures started on May 25th 2020
with collaborators gradually going back to work in staggered
schedules. From June 15th to June 30th 2020, 3–4 weeks after
easing up of confinement at NOVA University, we performed
a serosurvey on 1,636 university’s collaborators encompassing
seven distinct schools and the rectorate. In this study, we
estimated and characterized the antibody profile of a population
subgroup that had been under confinement to distinct extents
for the 3 months prior to the serosurvey. We found the overall
seroprevalence of SARS-CoV-2 spike specific IgG antibodies of
the NOVA university community to be 3%. Interestingly, SARS-
CoV-2 seroprevalence was 2–4-fold higher in the medical school
(6.20%) than in the other schools. This most likely is ascribed
to the fact that medical school faculty is composed mainly
by clinicians, which as essential workers were precluded from
confinement. Curiously, the seroprevalence of the collaborators
of the Institute for Tropical Health and Hygiene (4.26%), which
functions in articulation with hospitals, was 1.4-fold higher than
the overall prevalence. As a corollary of this study, we provide a
measure of prevalence of asymptomatic SARS-CoV-2 infections.
MATERIALS AND METHODS
Study Participants and Human Samples
For the setup of our ELISA assay, we used pre-pandemic plasma
samples originated from 3 cohorts: 43 samples from healthy
donors (HD), 138 samples from rheumatoid arthritis (RA)
patients and 35 samples from systemic lupus erythematosus
(SLE) patients. All pre-pandemic samples were collected
between 2016 and December 2019. In addition, we used
serum samples from 19 adult individuals that consulted
Hospital Fernando Fonseca between April and May 2020 and
were confirmed positive for SARS-CoV-2 by RT-PCR from
nasopharyngeal and/or oropharyngeal swabs in a laboratory
certified by the Portuguese National Health Authorities. The
detailed demographics and clinical characteristics of these
19 SARS-CoV-2 infected individuals are shown in Table 1.
Patients were clinically examined, scored for disease severity
and classified as: Asymptomatic-committed to the hospital for
other complaints, subjected to routine PCR-testing for SARS-
CoV-2 but upon medical examination did not exhibit any
signs nor symptoms; Mild disease- displayed fever, cough,
myalgias, or loss of taste and smell but did not require oxygen
supplementation; Moderate disease- required non-invasive
oxygen supplementation and hospitalization; Severe disease-
required invasive oxygen supplementation and patients were
committed to intensive care. NOVA University serum samples
(n = 1,636) were collected between June 15th and 30th 2020.
Serum/plasma were collected by whole blood centrifugation at
1,000×g for 10min at room temperature. Plasma/serum was
carefully aliquoted and stored at temperature controlled−80◦C
ultra-low freezer at CEDOC Biobank for subsequent analysis.
All samples were heat-inactivated at 56◦C for 60min. All
experiments and analyses from human donors were conducted
with the approval of local ethics committee, in accordance
with the provisions of the Declaration of Helsinki and the
GoodClinical Practice guidelines of the International Conference
on Harmonization.
Production of Trimeric Spike Protein
The construct encoding the trimeric pre-fusion stabilized
ectodomain of SARS-CoV2 spike (S) protein was kindly
donated by Dr Florian Krammer, Icahn School of Medicine
at Mount Sinai, New York, USA. Recombinant trimeric spike
protein was produced and purified at Instituto de Biologia
Experimental e Tecnológica (IBET), Oeiras, Portugal under
de Serology4COVID consortium, as previously described
(8, 9). In short, His-tagged trimeric spike was produced by
transient transfection of Expi293FTM cells (Thermo Fisher
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TABLE 1 | Comparison of demographic and clinical data between asymptomatic,
mild and severe group of COVID-19 patients.
Parameters Asymptomatic























SARS-CoV-2 PCR+ 100% 100% 100%
PCR+ days to serum
collection






















Bacterial Infection-n (%) 3 (60%) 4 (30.8%) 1 (100%)
CRP (mg/dL) 2.41 (0.78–5.38) 7.24
(2.63–12.61)#
0.41






Leukocyte (109/L) 4.6 (4.2–8.5) 8 (4.5–8.95) 22.3
Lymphocyte (109/L) 1.4 (0.9–1.8) 1.3 (0.8–1.5) 8.9
Procalcitonin (ng/mL) 0.11 (0.03–0.28)# 0.3 (0.13–0.67)# 0.06
*Clinical data missing for two donors. Median calculated out of total available data.
#Clinical data missing for one donor. Median calculated out of total available data.
CKC, chronic kidney disease; CRP, C-reactive protein.
Scientific) with a spike plasmid suitable for mammalian
cell expression (pCAGGS). All subsequent purification
steps were carried out at 4◦C. Three days post-transfection,
supernatants were collected filtered through Sartopore
MidiCaps, concentrated and dialysed with binding buffer
by tangential flow filtration, using 30 kDa membranes. The
dialysed and concentrated sample was filtered through 0.22µm
membrane and loaded into HisTrap HP columns, equilibrated
with binding buffer. Spike protein was eluted with a linear
gradient up to 500mM Imidazole. Fractions containing
Spike were concentrated to 1–2 mg/mL using Vivaflow 200
crossflow devices. Removal of imidazole and exchange to
PBS buffer was performed by diafiltration with 10 volumes of
PBS. Protein concentration was determined by absorbance at
280 nm combined with the specific extinction coefficient. The
concentrated and formulated products are filtered through
0.22µm membrane, aliquoted, snap frozen in liquid nitrogen
and stored at−80◦C.
ELISA Assay
A modified in-house ELISA was performed based on the
published protocol (8). Coating conditions were assayed by
antigen dilution with sera collected from 12 COVID-19 patients
and eight pre-pandemic samples collected between 2016 and
December 2019. Ninety six-well plates (Nunc, M9410) were used
to test coating concentrations ranging from 0.5 to 2µg/mL.
Sera/plasma were heat-inactivated at 56◦C for 1-h prior being
loaded in the in-house ELISA. High-binding 384-well ELISA
plates (Nunc, 735-0114) were coated with spike protein at
0.5µg/mL overnight at 4◦C. After washing three times with
0.1% PBS/Tween20 (PBST) using an automatic plate washer
(ThermoScientific), plates were blocked with 3% milk in 0.05%
PBST for 1 h at room temperature. Wells were emptied and
samples diluted 1:50 in 1% milk powder PBST were added and
incubated for 1 h at room temperature. Calibrators included sera
from PCR-tested SARS-CoV-2 infected individuals classified in
three groups according to their antibody titers: high-, moderate-
and low-antibody producers. Three individual samples from each
group were used. Negative controls included two pre-pandemic
samples and two blank wells. Following PBST washes, secondary
antibody was added at 1:25,000 dilution and incubated for 30min
at room temperature. IgA and IgG were detected using Goat anti-
Human IgA/IgG-HRP (abcam, ab97225/ab97215). Plates were
washed with PBST and 25 µL of TMB substrate (Biolgend,
421101) was added to the wells for ∼7min. The reaction was
stopped by adding 12.5 µL of 1M phosphoric acid (Sigma,
P5811) and read at 450 nm on a plate reader (BioTek). Two-
hundred and sixteen pre-pandemic plasma samples were used to
establish the assay cut-off value for seropositivity at 0.3987 for
IgG. The cut-off value resulted from the mean of OD450, values
from all negative controls plus 3 times the standard deviation.
ROC curve analysis determined a 99.53% specificity (with a CI95%
of 97.41–99.99%) and 94.74% sensitivity (with a CI95% of 73.97–
99.87%) at this cut-off for the serum dilution (1:50) used. The
cut-off of 0.3987 was applied uniformly to all assays and the
seropositivity was defined as any individual whose OD value lies
above the cut-off in serum diluted at 1:50. For IgA the assay cut-
off value for seropositivity was calculated in the similar manner
at 0.459. ROC curve analysis determined a sensitivity of 57.89%
(with a CI95% of 33.50–79.75%) and a specificity of 99.53% (with a
CI95% of 97.39–99.99%), at serum dilution 1:50. Inter- and intra-
assay coefficient of variability were found to be 5.3 and 2.7%,
respectively. Each plate contained 16 calibrators samples from
three high-, three medium-, and three low- antibody producers
and pools from all high-, medium- and low- antibody producers,
two pre-pandemic samples and two blank wells. Endpoint titers
were established using a 3-fold dilution series starting at 1:50 and
ending at 1:10,9350 and defined as the last dilution before the
signal dropped below OD450 of 0.15.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
(version 8.4.2). The non-parametric Kruskal-Wallis test was used
to compare the geometric ratios between groups. Spearman
correlation test was used in correlation analysis. The non-
parametric Man-Whitney test and Wilcoxon test were used as
described in figure legends.
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FIGURE 1 | Validation of SARS-CoV-2 ELISA assay. Levels IgG and IgA against trimeric spike protein of SARS-CoV-2 measured in the serum of SARS-CoV-2
PCR-positive individuals (n = 19) and pre-pandemic donors (n = 216) by absorbance at 450 nm (OD450). (A) Titration of trimeric Spike protein coating at 2, 1 and
0.5µg/mL by measuring IgG OD450 of 12 SARS-CoV-2 PCR-positive individuals (red) and eight pre-pandemic controls diluted at 1:50 (gray).
(Continued)
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FIGURE 1 | (B) Comparison of IgG levels between 19 SARS-CoV-2 PCR-positive individuals (red) and three pandemic cohorts: healthy donors (HD, n = 43),
rheumatoid arthritis (RA, n = 138) and systemic lupus erythematosus (SLE, n = 35), diluted at 1:50. Dashed line indicates test cut off. (C) ROC analysis plotting
specificity against sensitivity of samples as in (B). (D) Comparison of IgA levels between 19 SARS-CoV-2 PCR-positive individuals (red) and three pandemic cohorts:
healthy donors (HD, n = 43), rheumatoid arthritis (RA, n = 138) and systemic lupus erythematosus (SLE, n = 35), diluted at 1:50. Dashed line indicates seropositivity
threshold. (E) ROC analysis plotting specificity against sensitivity of samples as in (D). (F) Donor matched OD450 values for IgG and IgA of serum SARS-CoV-2
PCR-positive individuals diluted at 1:50. Dashed line indicate, orange: IgG seropositivity threshold, green: IgA seropositivity threshold. (G) Serial dilution for anti-spike
IgG (left) and anti-Spike IgG endpoint titers (right) according to disease classification (severe, mild and asymptomatic). (H) Serial dilution for anti-spike IgA (left) and
anti-Spike IgA endpoint titers (right) according to disease classification (severe, mild and asymptomatic). (I) Anti-Spike IgG and IgA endpoint titers in SARS-CoV-2
PCR-positive individuals segregated by sex. (J) Levels of IgG and IgA endpoint titers against age (females-maroon; males-blue). Data show individual sample values.
P-values ****p < 0.0001, **p < 0.01, *p < 0.05 were determined by Kruskal-Wallis test (B,D), Wilcoxon test (F), Man-Whitney test (I) and Spearman test (J).
RESULTS
SARS-CoV-2 Spike Protein ELISA Assay
Setup
Our serological assay uses the trimeric ectodomain of SARS-
CoV-2 spike protein as antigen and consists in a modified ELISA
protocol developed by Florian Krammer group at Mount Sinai’s
CLIA laboratory where it received New York State Department
of Health (NYSDOH) and FDA emergency use authorization
(8, 9). To set-up our ELISA assay we made use of serum from
19 individuals consulted at Hospital Fernando Fonseca that
were diagnosed positive for SARS-CoV-2 infection by RT-PCR
of nasopharyngeal and/or oropharyngeal swabs in a laboratory
certified by the Portuguese National Health Authorities. SARS-
CoV-2 infection may be asymptomatic or occur associated to
varied clinical manifestations including fever, asthenia, myalgia,
eventually progressing toward pneumonia and acute respiratory
distress (23, 24). Several comorbidities, such as cancer, diabetes
and cardiovascular disease may negatively influence COVID-19
severity and mortality (25). Demographics, reason for medical
admission (especially important in the case of asymptomatic
cases), and relevant co-morbidities for the 19 SARS-CoV-2 RT-
PCR positive individuals are contained in Table 1 together with
the results of PCR testing. When designing our assay setup, we
took care that our sampling of SARS-CoV-2-positive individuals
would reflect as well as possible the expected profile found in
the NOVA community in which this assay would be run, i.e.,
a population with mainly asymptomatic or paucisymptomatic
disease. To this end, we focus on SARS-CoV-2-positive group in
individuals undergoing routine visits to the hospital (e.g., child
delivery, oncology, cardiovascular or diabetes consults). Since
this population consults were not related with COVID-19, they
were composed almost exclusively (18 out of 19) of asymptomatic
or paucysimptomatic individuals, which reflects more closely the
general population.
First, we proceeded to titrate the concentration of trimeric
spike ectodomain used to coat ELISA plates, by comparing the
OD450 of IgG from 19 SARS-CoV-2 positive and eight pre-
pandemic samples diluted 1:50, when plates were coated with
2, 1, and 0.5µg/mL of spike (Figure 1A). Since spike protein
at 0.5µg/mL increased the dispersion of antibody production
profiling without functional loss in detection (Figure 1A), we
henceforth used the coating dose of 0.5 ug/mL in our serosurvey.
To establish the ELISA assay cut-off, we made use of 216 pre-
pandemic samples. Our pre-pandemic cohort (Table 2, n = 216)
was composed by 43 healthy donors (HD) and 183 patients with
TABLE 2 | Demographic characteristics of the study populations.
Pre-pandemic
HD RA SLE
n 43 138 35














Females-n (%) 42 (97.7) 118 (85.5) 34 (97.1)
Males-n (%) 1 (2.3) 20 (14.5) 1 (2.9)
chronic inflammatory diseases, rheumatoid arthritis (RA, n =
138) and systemic lupus erythematosus (SLE, n = 35), whose
dysregulated antibody increases the probability of displaying
cross-reactive antibodies against self and a variety of infections
(26). The assay cut-off was established at 0.3987, resulting
from the mean of the OD450 values from all negative controls
plus three times the standard deviation (8, 9). One of the
19 SARS-CoV-2 individuals did not seroconvert and four pre-
pandemic samples had OD450 values above cut-off (Figure 1B).
These four pre-pandemic individuals were later deemed as
false positives as the OD450 values were under the threshold
once the samples were diluted at 1:150. ROC curve analysis
determined a 94.74% sensitivity (with a CI95% of 73.97–99.87%)
and 99.53% specificity (with a CI95% of 97.41–99.99%) at
serum dilution (1:50) used (Figure 1C). As for anti-spike IgA,
the cut-off was established at 0.459 and only 11 out of 19
(57.8%) SARS-CoV-2 positive individuals had anti-spike IgA
antibodies at the time of the screen (Figure 1D). ROC curve
analysis determined a sensitivity of 57.89% (with a CI95% of
33.50–79.75%) and a specificity of 99.53% (with a CI95% of
97.39–99.99%), at serum dilution 1:50 (Figure 1E). We did not
detect any association between OD450 values of IgG and IgA
(Figure 1F).
Calculating end-point titers allows to be more exact in the
evaluation of the antibody response ensued and to compare
antibody production between distinct cohorts.We calculated IgG
and IgA endpoint titers of SARS-CoV-2 positive individuals by
serial 3-fold dilution and classified end-point titers of 1:150 as
low, 1:450 as moderate, and≥1:1,350 as high antibody producers,
as previously done (7). The majority of SARS-CoV-2 positive
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individuals were either moderate or high IgG/IgA antibody
producers (Figures 1G,H), and were similarly distributed in both
genders and across age distributions (Figures 1I,J).
This evaluation of titers dispersion by SARS-CoV-2 positive
individuals is important for the setup of our assay, since we
will use three samples of low-, three samples of medium-, and
three samples of high- antibody producers as quality calibrators
in each assay run, when testing our cohort. Additional quality
control calibrators will include pools of low-, medium-, and
high-antibody producers.
FIGURE 2 | IgG and IgA seroprevalence in NOVA University of Lisbon community. (A) Age and gender distribution of NOVA university study cohort (n = 1,636). (B)
Distribution of individuals with IgG titers of 1:150 (low producers), of 1:450 (moderate producers), and ≥1:1,350 (high producers); EPT: Endpoint titer (n = 50). (C)
Anti-Spike IgG endpoint titers in female and male donors (n = 50). (D) Levels of IgG endpoint titers against age (females-maroon; males-blue; n = 50). (E)
Donor-matched IgA and IgG OD450 values of plasma samples diluted at 1:50 (n = 50). Dashed line indicate, orange: IgG seropositivity threshold, green: IgA
seropositivity threshold. (F) Total number of tests performed in NOVA university organic units (gray) and number of positive tests (red) of each unit (NMS: Nova Medical
School; IHMT: Institute of Hygiene and Tropical Medicine; ITQB: Institute of Chemical and Biological Technology; SBE: NOVA School of Business and Economics; RET:
Rectory; FCT: School of Science and Technology; FCSH: School of Social and Human Sciences; ENSP: National School of Public Health. (G) Percentage of positive
test considering the total number of tests per organic unit. Data show individual sample values. P-values ****p < 0.0001 were determined by Man-Whitney test (C),
Spearman test (D) and Wilcoxon test (E).
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Seroprevalence in NOVA University
Community
NOVA University of Lisbon collaborators started to ease back
to presential work, in staggered schedules, on May 25th 2020.
An online registration form was sent to all collaborators of
NOVAUniversity of Lisbon and in order to encourage maximum
enrollment in the study, sample collection was performed in
all the schools and participants were offered a choice of which
location was more convenient to them. Two to three weeks
later, we collected 1,645 plasma samples from NOVA university
collaborators, but demographic data were absent for 9 donors and
analysis was restricted to the 1,636 donors that we had available
data. Gender distribution was 66% female and 34% male, with
ages comprehended between 17 and 76 years (Figure 2A). Study
participants self-reported as asymptomatic or paucisymptomatic
and had not been diagnosed with COVID-19, with only one
having been tested positive by PCR. We found that 50 of
1,636 study participants presented anti-spike IgG. Of those,
22% were high (end-point titers ≥1:1,350), 42% were moderate
(end-point titers 1:450), and 30% were low (end-point titers
1:150) antibody producers (Figure 2B). Anti-SARS-CoV-2 IgG
antibodies were detected in 34 (68%) women and 16 (32%) men,
which reflects the gender distribution of the recruited cohort
(66% female and 34% male). In moderate and severe COVID-
19 disease women have been found to have higher antibody
titers than men (27–30). However, this does not appear to be the
case in asymptomatic and mild disease (31, 32). In agreement,
our study group, composed overwhelming of asymptomatic
individuals, did not provide any differences in IgG end-point
titers between females and males (Figure 2C). Only three of the
seroconverters were older than 60 years old, consequently, we are
unable to draw any conclusion about how antibody titers vary
with age in asymptomatic SARS-CoV-2 infections (Figure 2D).
Finally, none of IgG seropositive participants had detectable IgA
(Figure 2E). The distinct schools complied to the confinement
to distinct extents, in view of the specifics of their faculties.
To gain some insight into the efficacy of the confinement
measures, we reanalyzed our data disaggregated by organic
unit: Nova Medical School (NMS); Institute of Hygiene and
Tropical Medicine (IHMT); Institute of Chemical and Biological
Technology (ITQB); NOVA School of Business and Economics
(SBE); Rectory (RET); School of Science and Technology (FCT);
School of Social and Human Sciences (FCSH); and National
School of Public Health (ENSP). A great extent of Medical School
(NMS) faculty consists of practicing clinicians, who, as health
care providers, are considered essential workers and exempt from
the national decreed confinement. In line with this confinement
exemption, we found that anti-SARS-CoV-2 seroprevalence at
medical school at 6.20% to be more than 2-fold higher than
the average for the university. On the other extreme was the
School of Social and Human Sciences (FCSH) that at 1.60%
had approximately half of the averaged university seroprevalence
(Figures 2F,G).
These data indicate that confinement measures may be
efficient at containing SARS-CoV-2 transmission.
DISCUSSION
Recent data suggest that IgG antibodies specific for SARS-CoV-2
spike protein persist for at least a fewmonths (7, 32). Serosurveys,
in particular the ones aimed at detecting anti-spike IgG can
potentially estimate the total number of infections, regardless of
whether an infection was subclinical at least within this time-
frame (7). Here, we setup a serological assay to detect antibodies
against spike trimeric ectodomain 3–4 weeks after the easing up
of the confinement measures.
In this assay, we used trimeric spike accounting not only
the neutralizing antibodies targeting RBD sequence, but also
additional epitopes which are suspected to contribute to the
overall antibody response (9, 11, 33, 34). To validate the assay, we
used serum collected from 19 SARS-CoV-2 positive individuals
11–24 days after RT-PCR testing, a time window when
seroconversion has been shown to occur (35–38) and consistent
with these previous reports, all but one of the 19 SARS-CoV-2 had
seroconverted. Our SARS-CoV-2 positive group encompassed
high-, medium-, and low-antibody producers that we then
used as internal quality controls to insure the reproducibility
and calibration of our assay setup. Importantly, we actively
sought that our SARS-CoV-2-positive group would reflect as
much as possible the antibody production profile of the general
population. In order to do this, rather than recruiting COVID-
19 patients, we recruited SARS-CoV-2-positive individuals with
overwhelming (18 out of 19) asymptomatic or paucisymptomatic
infection. The fact that they were recruited at a major central
hospital, was convenient since it ensured that they would not only
be screened for SARS-CoV-2, as a routine screening measure,
but also that they could be evaluated by clinicians, which could
appropriately classify their disease status. We cannot exclude that
the reasons that brought the individuals to the hospital, might
have affected their antibody response. However, the fact that they
were undergoing routine consults plus the advantage of having
their SARS-CoV-2 disease status assessed by clinicians, in our
opinion, outweighs the possible limitations. Moreover, it would
have been logistically difficult to screen asymptomatic individuals
outside a health care environment. It is a fact that we have used
a limited number of SARS-CoV-2-positive individuals to setup
our assays, however the number used is well within the one used
in similar studies (3, 11, 31, 32). In addition, variations of this
ELISA test developed by Florian Krammer laboratory has been
used by multiple groups worldwide. Nonetheless, ideally, SARS-
CoV-2-positive individuals should have been recruited from the
wide community in a high enough number to ensure the desired
performance characteristics of the assay.
In the assay validation we looked if previous conditions
that increase the production of antibodies, namely chronic
inflammatory diseases such as RA and SLE, could contribute to
the assay’s background. Even though we detected one RA and
one SLE patient with OD450 values for IgG well above cutoff, no
statistically significant difference was observed when compared
to healthy donors. In locations with low prevalence of SARS-
CoV-2 infections, serological assays specificity is recommended
to be at least 98% (22). Our assay had a sensitivity of 94.74%,
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specificity of 99.53% with a positive predictive value (PPV) and
negative predictive value (NPV) for the found 3% prevalence in
the study population of 86.18 and 99.84%, respectively.
Portuguese government decreed national confinement on
March 16th 2020 when the official number of SARS-CoV-
2 infections reached 331 in a population of ∼10 million,
with schools closing and remote work enforced when possible.
However, it is suspected that the number of cases nation-
wide might have been higher than 331, since at the time only
symptomatic individuals and those having close contact with
confirmed patients were being tested. Serosurveys allow for a
more rigorous estimate of COVID-19 prevalence by detecting
asymptomatic and paucisymptomatic infections in addition to
the symptomatic ones. In this study, we performed serological
tests to ∼30% of university staff, 3–4 weeks after the easing
up of the confinement measures and found a SARS-CoV-2
seroprevalence of 3.0%.
The isotype of the antibody response to SARS-CoV-2 may
function as indicators of the type and duration of the immune
response. Antibodies of IgA isotype are key to eliminate the
virus at the upper respiratory tract mucosal. In COVID-19
disease, IgA antibody production starts early upon infection
(∼5 days), peaks at 12 day and starkly decreases thereafter
(39). As for IgG, it mediates systemic immune responses and
it is longer-lasting, with studies pointing that SARS-CoV-2 IgG
antibodies could last up until 4 months (7). Notwithstanding,
the final duration of SARS-CoV-2 IgA and IgG antibody
responses can only be fully characterized in longer, and on-going,
longitudinal studies.
The fact that we could only detect IgG, but not IgA, antibodies
in NOVA community indicates that in none of the infections
took place in the 2–3 week time span between the easing up
of the confinement measures and the serosurvey. Moreover, it
leaves opens the possibility that the exposure to SARS-CoV-2
might have occurred prior to the enactment of the confinement
measures. However, it is impossible to exclude that SARS-CoV-2
exposure might have occurred during confinement.
In our study the participants self-reported as having been
asymptomatic or paucisymptomatic in the 3 months prior.
Nonetheless, their breadth of antibody production spanned
from low to high producers and was in line to the one
observed in individuals with clinical signs of COVID-19. Even
though a previous report had proposed that asymptomatics
possessed lower levels of anti-SARS-CoV-2 IgG antibodies than
symptomatic individuals (1), others have observed equivalent
IgG production in asymptomatic vs. symptomatic SARS-CoV-2
(21). More studies will be needed to fully characterize antibody
production by different SARS-CoV-2 presentations.
Previous studies have shown that the immune response to
infection is different in women than in men (40, 41). In the case
of hospitalized COVID-19 patients, recent studies have shown
that women mount a different immune response, produce higher
antibody titers and have less mortality (27, 28). However, the
association between gender and antibody titers appears to be
less clear in mild or asymptomatic SARS-CoV-2 infection with
men and women producing similar antibody titers (31, 32).
Similarly, in our cohort of asymptomatic or paucisymptomatic
individuals we did not detect significant differences in antibody
titers between men and women.
The assessed seroprevalence of 3% is low, nonetheless it’s in
alignment with the seroprevalence observed in national surveys
(18, 19), as well as surveys of local communities (42). Moreover,
it is in line with the national survey results involving 2,100
participants and performed in the same post-confinement time
window, which found a seroprevalence of 2.9% (https://www.
publico.pt/2020/07/31/ciencia/noticia/inquerito-serologico-
44-pessoas-anticorpos-sintomas-covid19-1926595). Since
confinement measures were implemented national wide, with
only exceptions for essential workers, in order to have an idea
of the efficacy of the confinement measures we broke down our
analysis by school. The medical school stood out, as its faculty
is mainly composed of practicing clinicians, who, as essential
workers could not comply to the confinement measures. Medical
school seroprevalence was, at 6.20%, more than 2-fold of the
university average and it was ∼4-fold higher than the one
observed at the School of Social and Human Sciences (FCSH).
The seropositive cases identified at medical school were not
linked COVID-19 patient care. Moreover, Portuguese hospitals
implemented routine RT-PCR testing and adopted personal
protective equipment, measures shown to dampen the risk of
transmission in a clinical setting (31, 43). Even though, it is
possible that, at least part, of higher seroprevalence in medical
school might be due to viral transmission in a social activities
(meals, transportation, etc.), we are unable to completely
extricate the contribution of non-compliance to confinement
from the higher exposure risk in a hospital setting.
Our study has other limitations, as our population sampling
is biased and it does not reflect the entire population, namely
children and elderly are absent. Our participation rate (∼30%),
might both enrich for people that suspected having had contacts
or mild symptoms, or, on the contrary, be under representative
of people with higher risk of infection.
In conclusion, our study suggests that confinement
measures might have played a mitigative effect in SARS-
CoV-2 transmission and that essential workers have a 2-fold
increase in viral exposure, when compared to non-essential
workers that observed confinement. Additional serological
surveys in different population subgroups encompassing distinct
types of essential workers will paint a broader picture of the effect
of the confinement measures in the broader community.
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